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Chronic kidney disease (CKD) is currently considered a major comorbidity in patients 
affected by HIV infection. In addition, new generation antiretroviral drugs that inter-
act with creatinine transporters were recently introduced. Rilpivirine, dolutegravir, 
and cobicistat, with different mechanisms, inhibit the amount of tubular secretion 
of creatinine causing a slight increase in serum creatinine levels and consensual 
e GFRcreat reduction. This will require an unprecedented attention to renal issues, 
because the new drugs can also be associated to old antiretroviral drugs that may 
exert renal toxic effects. Owing to the interference of these drugs with creatinine 
secretion, an alternative way of estimating GFR would be desirable. At the moment, 
methods of direct GFR measurement have a high impact on the patient, are not 
readily available, or are not reliable in HIV patients. Consequently, use of classic for-
mulas to estimate GFR is still recommended, considering the apparent reduction of 
eGFRcreat due to these drugs. Tubular function needs to be carefully monitored with 
simple tests such as proteinuria, phosphatemia, urinary excretion of phosphate, 
normoglycemic glycosuria, and excretion of uric acid. More specifi c and sensi-
tive markers of tubular damage are still not readily available in all clinical labs. HIV 
patients treated by the novel drugs need to be monitored on a monthly basis for the 
fi rst 3 months. Subsequent monitoring should be performed on a quarterly basis or 
guided by comorbidities. Key words: cobicistat, dolutegravir, HIV, kidney, rilpivirine
CHRONIC KIDNEY DISEASE AND HIV 
INFECTION
Chronic kidney disease (CKD) is currently con-
sidered a major comorbidity in patients who are 
affected by HIV infection.1,2 The increase in life 
expectancy that followed the introduction of com-
bination antiretroviral therapy (cART) induced the 
emergence of common chronic conditions, such 
as diabetes and hypertension, that act as major 
pathogenic determinants for the development of 
CKD.2,3 Moreover, chronic infl ammation caused 
by the infection and probably direct renal damage 
mediated by viral products on kidney biology are 
contributory factors for the onset of CKD in these 
subjects. Finally, the potential toxic effect of some 
antiretroviral agents, such as indinavir or tenofovir 
(TDF), is well known with a body of evidence.4-6 
Although these drugs may rarely induce clinically 
evident nephrotoxic renal damage, they more often 
represent a cofactor in the determinism of CKD.
NOVEL ANTIRETROVIRAL DRUGS
In addition to this complex scenario, new anti-
retroviral drugs that interact with creatinine 
transporters have recently become available. These 
drugs present a good safety and tolerability profi le, 
which gives them better security and manage-
ability compared to older drugs. However, some 
apparent concerns may arise from their reported 
effects on renal function.
The fi rst of these compounds is rilpivirine, a non-
nucleoside reverse transcriptase inhibitor (NNRTI). 
Rilpivirine has a high protein-binding capacity and 
is excreted only minimally by the kidney.
In 2 large trials, rilpivirine determined a consis-
tent increase of serum creatinine (SCr) (an average 
of approximately 0.1 mg/dL) in patients with nor-
mal renal function.7,8 This increase was stable over 
time and was not associated with other laboratory 
parameters of kidney damage; in turn, it affected 
GFR estimation based on creatinine (eGFRcreat).
Rilpivirine has been reported to act as an inhibi-
tor of the renal organic cationic transporter (OCT2) 
at the basolateral side of proximal renal tubular 
cells (Figure 1)9 in a way that mimics the effects 
of cimetidine, quinidine, or trimethoprim; all 
these drugs decrease the secretion of creatinine 
by the proximal renal tubule.10 GFR estimated by 
formulas based on serum cystatin c (eGFRcys) does 
not show the above-mentioned reduction under 
rilpivirine therapy. However, caution in using 
these formulas is suggested, because of possible 
variations in cystatin c generation according to the 
virological status of the patient.11
Dolutegravir is a novel integrase inhibitor that is 
metabolized by hepatic UGT1A1 with a minor role 
of CYP3A. Renal elimination of unchanged dolute-
gravir is less than1%.12 In a comparison study of 
dolutegravir versus raltegravir (SPRING), a small 
increase in creatinine was observed in the dolute-
gravir arm.13 This slight, nonprogressive, initial 
increase in SCr by dolutegravir is in the range of 
0.1 to 0.15 mg/dL and has been demonstrated not 
to affect actual glomerular fi ltration rate (a-GFR), 
measured by the iohexol clearance.14,15
In this case, in vitro and clinical data are consis-
tent with inhibition of the OCT2.12 This transporter 
is positioned at the basolateral side of the proximal 
renal tubular cells and is responsible for the uptake 
of creatinine by the proximal renal tubular cells from 
Figure 1. Renal tubular transporters. Urinary creatinine is secreted by tubule at approximately 10% of 
total amount. Creatinine is an endogenous substrate of OCT2 (uptake in tubule cells).10, 32 Creatinine effl ux 
in urine seems mediated by MATE1 and MATE2-K.
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After initiating the cART, with reduction and pos-
sibly disappearance of HIV RNA from circulation 
and an increase in CD4 cells, the cystatin C produc-
tion rate declines. As a result, patients starting their 
fi rst cART treatment show an increase of eGFR of 
20 to 25 mL/min when they change from the initial 
viremic and systemic infl amed state to a chronic 
nonviremic condition; this increment is mostly 
apparent and is at least in part due to the reduced 
serum levels of cystatin C.21
MANAGEMENT OF HIV PATIENTS TREATED 
WITH THE NOVEL DRUGS
GFR can be estimated by applying validated for-
mulas such as the CKD-EPI based on creatinine to 
monitor renal function in patients treated with one 
of the above-mentioned drugs.23 Antiretroviral regi-
mens that include rilpivirine, dolutegravir, or cobici-
stat will produce an apparent reduction of eGFRcreat 
that, in normal conditions, should not exceed 25% 
compared with the basal level. A greater reduction 
of eGFRcreat needs to be evaluated carefully, because 
it may represent a sign of true renal function impair-
ment. Patients who have a basal GFR lower than 60 
mL/min/1.73 m2 may experience an even higher 
reduction of eGFR, owing to the proportionally 
greater tubular secretion that accounts for creatinine 
excretion in conditions of moderate renal impair-
ment. In these conditions, tubular secretion may be 
higher than 35% of total excretion.24
In addition to the evaluation of glomerular fi l-
tration, the tubular function needs to be carefully 
monitored. Simple tests may help manage this issue. 
Proteinuria should always be looked for in patients 
who are exposed to potential nephrotoxic drugs. 
Dipstick proteinuria has a high negative predic-
tive value, but a low positive predictive value.25 It 
can only be a screening test. Any patient with an 
altered dipstick proteinuria needs a more accurate 
evaluation. We recommend performing quantitative 
proteinuria estimation as total protein and albumin 
over creatinine ratio (PCR and ACR, respectively). 
These measurements can be done on morning spot 
urine samples, which avoids the burden of timely 
collected urine. ACR greater than 30 mg/g indicates 
moderately increased albuminuria; if it is greater 
than 300 mg/g, it is a sign of severe albuminuria or 
frank proteinuria.26 PCR higher than 150 mg/g is 
also an altered value. The ratio between ACR and 
PCR may help discriminate between glomerular 
and tubular proteinuria. A ratio greater than 0.4 
blood. Competitive pharmacological inhibition of 
OCT2 halts tubular secretion of creatinine (Figure 1).
Cobicistat is a new pharmacokinetic enhancer, 
metabolized by CYP3A, that does not have any 
antiretroviral property per se.16 Cobicistat provokes 
an increase in SCr and a decrease in eGFR based on 
creatinine measurement. Previous research has 
demonstrated that cobicistat is a potent inhibitor 
of MATE1 (Human Multidrug and Toxic Extrusion 
1), which is present at the apical side of proximal 
renal tubular cells and is responsible for the effl ux 
of creatinine from the tubular cells17 (Figure 1). 
Therefore, cobicistat inhibits the amount of tubular 
secretion of creatinine and causes a slight (<10%) 
increase in serum creatinine levels and consensual 
eGFRcreat reduction, without other evidence of kid-
ney damage. This laboratory changes are promptly 
reversible upon drug withdrawal.
PROBLEM OF RENAL FUNCTION MONITORING
Based on all the considerations about the new 
antiretroviral drugs, the introduction of these vari-
ous therapeutic agents requires that careful atten-
tion is paid to renal issues. Also, the new drugs 
can be associated to old antiretroviral drugs that, 
under certain conditions, may exert renal toxic 
effects. Therefore, patients who will be exposed 
to rilpivirine, cobicistat, and dolutegravir must be 
monitored with simple and reliable parameters of 
renal dysfunction, including indicators of GFR and 
tubular damage.
Owing to the interference of these new drugs 
with tubular creatinine secretion, it would be desir-
able to have an alternative way of estimating GFR. 
However, at the moment, the issue cannot be eas-
ily resolved. On the one hand, methods of direct 
GFR measurement, such as inuline, iohexol, or 
iothalamate plasma or renal clearances, would help 
overcome this drawback. Nevertheless, all these 
methods have a high impact on the patient, require 
repeated blood sampling, and are not readily avail-
able in common clinical labs because they require 
complex analytical procedures. On the other hand, 
formulas that estimate GFR and are based on cys-
tatin C, even though they have good performance 
in the general population,18 are not useful in HIV 
patients, because production of cystatin C is not 
constant during the different phases of the infec-
tion. Patients with detectable viremia and low CD4 
count tend to have a higher production of this mol-
ecule, with concomitant higher plasma levels.19-22 
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Tubular proteinuria can also be detected by 
specific markers such as urinary excretion of 
retinol binding protein, α-1-microglobulin, β-2-
microblobulin, and NGAL (neutrophil gelatinase-
associated lipocalin).28 These are sensitive markers 
of tubular damage, yet are not readily available in 
all clinical labs.
Tubular dysfunction can also be assessed as an 
increased urinary excretion of phosphate, better 
estimated as the TmPO4/GFR ratio and as hypo-
phosphatemia (<2.5 mg/dL).29An increased 
fractional excretion of uric acid can also be easily 
assessed and is a marker of early tubular dam-
age. Finally, normoglycemic glycosuria appears 
as an advanced sign of tubular dysfunction.30
We suggest that HIV patients who are treated 
by potential nephrotoxins, especially in associa-
tion with the novel drugs that affect creatinine 
excretion, need to be monitored on a monthly 
basis for the fi rst 3 months. Patients who experi-
ence a decrease of eGFRcreat greater than 25% or 
show the de novo occurrence of signs of tubular 
dysfunction need a nephrological consult. Gen-
erally, new abnormalities attenuate after week 16 
of cART.31 Consequently, for abnormalities that 
are not present by week 16, subsequent monitor-
ing should be performed on a quarterly basis or 
guided by comorbidities.
In conclusion, the introduction of new anti-
retroviral agents that potentially affect renal 
function and their foreseeable wide therapeutic 
application in the near future is raising some 
concerns. Clinicians should carefully monitor 
renal function to identify possible alterations 
suggestive of a true renal functional impair-
ment. Patients should also be monitored for the 
presence of other risk factors for kidney disease, 
such as growing age of HIV patients and puta-
tive nephrotoxicity of other drugs in the ARV 
regimens. Results from clinical trials conducted 
with these novel agents are in some way reas-
suring, but physicians in routine clinical practice 
will need evaluation strategies for the long-term 
surveillance of eventual toxicities.
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